New combo shows promise for Drug-Resistant lung cancer

NCT ID NCT04245085

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This study tested a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus chemotherapy in 95 people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The goal was to see if this new mix could help control the cancer for at least a year. The trial was completed and results are being analyzed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFRMUTANT STAGE IIIB/C OR IV NON-SQUAMOUS NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asklepios Fachkliniken München-Gauting

    München, Germany

  • Complejo Hospitalario de Jaén

    Jaén, Spain

  • Hospital De La Santa Creu I Sant Pau

    Barcelona, Spain

  • Hospital General de Valencia

    Valencia, Spain

  • Hospital Puerta de Hierro

    Madrid, Spain

  • Hospital Teresa Herrera

    A Coruña, Spain

  • Hospital Universitario Fundacion Jimenez Díaz

    Madrid, Spain

  • Hospital Universitario Insular Gran Canaria

    Las Palmas de Gran Canaria, Spain

  • Hôpitaux Universitaires de Genève

    Geneva, Switzerland

  • ICO - Hospital Universitari Germans Trias i Pujol

    Badalona, Spain

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

  • LungenClinic Grosshansdorf

    Großhansdorf, Germany

  • National Cancer Center

    Goyang, South Korea

  • National University Hospital

    Singapore, Singapore

  • OSI Bilbao Basurto

    Bilbao, Spain

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • UniversitätsSpital Zürich

    Zurich, Switzerland

  • Vall d'Hebron University Hospital

    Barcelona, Spain

Conditions

Explore the condition pages connected to this study.